KIMI IGUCHI - 28 Nov 2023 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role
CFO & Treasurer
Signature
/s/ Jennifer Fitzpatrick, as Attorney-in-Fact for Kimi Iguchi
Issuer symbol
SAGE
Transactions as of
28 Nov 2023
Net transactions value
-$18,172
Form type
4
Filing time
30 Nov 2023, 16:04:41 UTC
Previous filing
17 Mar 2023
Next filing
04 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SAGE Common Stock Award $0 +3,500 +5.3% $0.000000 69,730 28 Nov 2023 Direct F1, F2
transaction SAGE Common Stock Tax liability $18,172 -943 -1.4% $19.27 68,787 28 Nov 2023 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On March 25, 2020, the reporting person was granted Performance Stock Units (PSUs) to acquire a total of 8,750 shares of common stock. The PSUs vest upon the achievement of certain milestones, one of which was met on November 28, 2023, resulting in the vesting of the PSUs as to 3,500 shares.
F2 Reflects beneficial ownership balance which includes 670 shares purchased on June 30, 2023 under the Sage Therapeutics, Inc. 2014 Employee Stock Purchase Plan.